Company intelligence / Profile preview
Berna Biotech AG
- Ownership
- Private
- Employees
- ~300
- Development stage
- Commercial
Overview
Berna Biotech was a leading global vaccine developer and manufacturer with a history dating back to its founding as the Swiss Serum and Vaccine Institute in 1898. It developed over twenty commercialized vaccines targeting major infectious diseases. The company was acquired by Crucell in 2006 but its legacy continues through ongoing programs and collaborations such as those with the Swiss Biotech Center on next-generation COVID‑19 vaccines using advanced VLP technologies. Its Korean affiliate remains active.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- VaccinesMonoclonal antibody
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Berna Biotech AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Berna Biotech AG.